Core Insights - Getty Images Holdings, Inc. reported a quarterly loss of $0.14 per share, significantly missing the Zacks Consensus Estimate of $0.03, marking an earnings surprise of -566.67% [1] - The company generated revenues of $224.08 million for the quarter ended March 2025, which was 4.71% below the Zacks Consensus Estimate, but slightly above the year-ago revenues of $222.28 million [2] - The stock has underperformed the market, losing about 13% since the beginning of the year compared to the S&P 500's decline of -3.8% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.03 on revenues of $236.26 million, and for the current fiscal year, it is $0.10 on revenues of $948.07 million [7] - The estimate revisions trend for Getty Images is currently unfavorable, resulting in a Zacks Rank 5 (Strong Sell), indicating expected underperformance in the near future [6] Industry Context - The Internet - Software industry, to which Getty Images belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a relatively strong industry performance [8] - Another company in the same industry, Domo, is expected to report a quarterly loss of $0.20 per share, with revenues projected to decline by 2.8% year-over-year [9]

Core Viewpoint - Karyopharm Therapeutics reported a quarterly loss of $2.77 per share, significantly better than the Zacks Consensus Estimate of a loss of $4.21, marking an earnings surprise of 34.20% [1] Financial Performance - The company posted revenues of $30.02 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 16.18%, compared to $33.13 million in the same quarter last year [2] - Over the last four quarters, Karyopharm has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Karyopharm shares have declined approximately 40.7% since the beginning of the year, while the S&P 500 has decreased by 3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$3.90 on revenues of $39.29 million, and for the current fiscal year, it is -$14.05 on revenues of $150.29 million [7] Industry Outlook - The Medical - Drugs industry, to which Karyopharm belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Company Performance - Aquestive Therapeutics reported a quarterly loss of $0.24 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.17, representing an earnings surprise of -41.18% [1] - The company posted revenues of $8.72 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 28.14%, and down from $12.05 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Performance - Shares of Aquestive Therapeutics have declined approximately 21.6% since the beginning of the year, compared to a decline of -3.8% for the S&P 500 [3] - The current Zacks Rank for the stock is 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $11.87 million, and for the current fiscal year, it is -$0.65 on revenues of $49.55 million [7] - The estimate revisions trend for Aquestive Therapeutics is currently unfavorable, which may change following the recent earnings report [6] Industry Context - The Medical - Drugs industry, to which Aquestive Therapeutics belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a relatively strong industry performance [8]

Company Performance - FibroGen reported a quarterly loss of $0.16 per share, significantly worse than the Zacks Consensus Estimate of $0.03, representing an earnings surprise of -633.33% [1] - The company posted revenues of $2.74 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 71.19%, but down from $55.9 million in the same quarter last year [2] - Over the last four quarters, FibroGen has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Movement and Outlook - FibroGen shares have declined approximately 41.8% since the beginning of the year, compared to a -3.8% decline in the S&P 500 [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.09 for the coming quarter and -$0.60 for the current fiscal year [4][7] - The current estimate revisions trend for FibroGen is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which FibroGen belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact FibroGen's stock performance [5]

Company Performance - Cue Biopharma reported a quarterly loss of $0.17 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.14, representing an earnings surprise of -21.43% [1] - The company posted revenues of $0.42 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 78.95%, compared to revenues of $1.72 million a year ago [2] - Over the last four quarters, Cue Biopharma has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Movement and Outlook - Cue Biopharma shares have declined approximately 28.5% since the beginning of the year, while the S&P 500 has only declined by 3.8% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.14 on $2 million in revenues, and -$0.58 on $8.36 million in revenues for the current fiscal year [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Cue Biopharma belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The Zacks Rank for Cue Biopharma is currently 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6]

Core Viewpoint - Root, Inc. (ROOT) shows a significant improvement in earnings outlook, making it an attractive investment option as analysts continue to raise earnings estimates for the company [1][3]. Earnings Estimate Revisions - The upward trend in earnings estimate revisions indicates growing analyst optimism regarding Root's earnings prospects, which is expected to positively impact its stock price [2]. - For the current quarter, Root is projected to earn $0.44 per share, reflecting a remarkable increase of +184.62% compared to the same period last year. Over the last 30 days, the Zacks Consensus Estimate for Root has risen by 144.44% due to one upward revision and no negative changes [7]. - For the full year, the earnings estimate is $1.11 per share, which is a decrease of -35.84% from the previous year. However, there has been a positive trend in estimate revisions, with one estimate moving up and pushing the consensus estimate up by 513.89% [8][9]. Zacks Rank and Performance - Root currently holds a Zacks Rank 1 (Strong Buy), supported by favorable estimate revisions. The Zacks Rank system has a proven track record, with Zacks 1 Ranked stocks averaging an annual return of +25% since 2008 [3][10]. - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have been shown to significantly outperform the S&P 500 [10]. Recent Stock Performance - Over the past four weeks, Root shares have increased by 22.9%, indicating investor confidence in the company's earnings growth prospects due to the positive estimate revisions [11].

Core Viewpoint - Fox (FOXA) reported quarterly earnings of $1.10 per share, exceeding the Zacks Consensus Estimate of $0.93 per share, and showing a slight increase from $1.09 per share a year ago, indicating a positive earnings surprise of 18.28% [1][2] Financial Performance - The company achieved revenues of $4.37 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.30%, and reflecting a significant increase from $3.45 billion in the same quarter last year [2] - Over the last four quarters, Fox has consistently surpassed consensus EPS estimates four times and topped revenue estimates three times [2] Stock Performance - Fox shares have increased approximately 3.4% since the beginning of the year, contrasting with the S&P 500's decline of -3.8% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations for it to outperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.12 on revenues of $3.08 billion, and for the current fiscal year, it is $4.45 on revenues of $15.88 billion [7] - The trend of estimate revisions for Fox has been favorable leading up to the earnings release, which may influence future stock movements [5][6] Industry Context - The Broadcast Radio and Television industry, to which Fox belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

Agenus (AGEN) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $3.04 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 36.02%. A quarter ago, it was expected that this biotechnology company would post a loss of $2.36 per share when it actually produced a loss of $2.04, delivering a surprise of 13.56%. Ahead of this earnings release, the estimate r ...

分组1 - Chegg reported a quarterly loss of $0.06 per share, missing the Zacks Consensus Estimate of a loss of $0.01, compared to earnings of $0.26 per share a year ago, representing an earnings surprise of -500% [1] - The company posted revenues of $121.39 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 6.03%, but down from $174.35 million year-over-year [2] - Chegg shares have declined approximately 57.1% since the beginning of the year, contrasting with the S&P 500's decline of -3.8% [3] 分组2 - The earnings outlook for Chegg is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend for estimate revisions for Chegg is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is $0.02 on revenues of $112.36 million, and $0.06 on revenues of $435.05 million for the current fiscal year [7] 分组3 - The Internet - Software industry, to which Chegg belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]

CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 50%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.20 per share when it actually produced earnings of $0.22, delivering a surprise of 210%. Over the last four quart ...